Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

NCT: NCT04342546 · RECRUITING

NCT IDNCT04342546
StatusRECRUITING
Start Date2020-12-11
Completion2031-12-10

Brief Summary

This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.

Frequently Asked Questions

What is Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction?

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction is a clinical trial registered under NCT04342546. Current status: RECRUITING.

What is the status of NCT04342546?

The current status of NCT04342546 (Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction) is: RECRUITING.

When did Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction start?

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction started on 2020-12-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑